Internal Medicine: Step-by-Step Guide on How to Write SOAP Notes

Updated January 2026

Internal medicine SOAP notes require comprehensive documentation that addresses the full spectrum of adult patient care - from acute illness management to chronic disease optimization and preventive health maintenance. Internists serve as the central coordinators for complex patients with multiple comorbidities, making thorough documentation essential for care continuity, quality reporting, and optimal patient outcomes. This guide provides detailed instructions for documenting internal medicine encounters following AMA documentation guidelines and CMS 2026 requirements.

Create Your Internal Medicine SOAP Note in 2 Minutes

Start with 20 free SOAP notes. No credit card required.

Unique Aspects of Internal Medicine Documentation

Internal medicine documentation differs from other specialties in several critical ways:

  1. Comprehensive Care Coordination: Internists manage multiple chronic conditions simultaneously, requiring integrated documentation approaches
  2. Complex Patient Populations: Patients often have 5+ chronic conditions with polypharmacy considerations
  3. Preventive Care Integration: Health maintenance and USPSTF-guided screening must be documented alongside acute and chronic care
  4. Chronic Disease Management: Diabetes, hypertension, and hyperlipidemia protocols require standardized documentation for quality measures
  5. Medication Reconciliation: Comprehensive medication management is central to every encounter
  6. Risk Stratification: Cardiovascular, diabetes, and cancer risk assessments guide preventive interventions
  7. Quality Measures Reporting: MIPS/MACRA quality metrics require specific documentation elements
  8. Care Transitions: Hospital follow-up and specialist coordination documentation is essential

Subjective Section (S)

The Subjective section in internal medicine must capture a comprehensive history that addresses both acute concerns and the ongoing management of chronic conditions, while also documenting health maintenance needs.

Subjective Section (S) Components

  1. Chief Complaint:

    • Primary reason for visit with duration
    • May include multiple concerns for complex patients
    • Example: "Annual wellness visit with medication refill; also concerned about increased fatigue x 2 weeks"
  2. History of Present Illness:

    • Detailed description of acute symptoms with OLDCARTS elements
    • Chronological narrative of symptom development
    • Impact on daily functioning
    • Example: "58-year-old male with progressive fatigue over 2 weeks. Reports needing to rest after climbing one flight of stairs. Associated with mild exertional dyspnea. No chest pain, orthopnea, or edema. No fever, weight loss, or night sweats."
  3. Chronic Disease Review:

    • Status of each chronic condition since last visit
    • Symptom control assessment
    • Self-management behaviors (diet, exercise, monitoring)
    • Recent hospitalizations or ER visits
    • Example: "Diabetes: Blood sugars ranging 120-180 fasting per home log. No hypoglycemia. Checking BG 2x daily. Following diabetic diet with occasional lapses."
  4. Comprehensive Review of Systems:

    • Constitutional: Weight changes, fatigue, fever, night sweats
    • HEENT: Vision changes, hearing, dental issues
    • Cardiovascular: Chest pain, palpitations, edema, claudication
    • Respiratory: Dyspnea, cough, wheezing
    • GI: Appetite, nausea, bowel changes, GERD symptoms
    • GU: Urinary symptoms, sexual function, menstrual history
    • Musculoskeletal: Joint pain, stiffness, weakness
    • Skin: Rashes, lesions, changes in moles
    • Neurological: Headaches, numbness, weakness, cognitive changes
    • Psychiatric: Mood, anxiety, sleep, stress
    • Endocrine: Heat/cold intolerance, polyuria, polydipsia
    • Hematologic/Lymphatic: Easy bruising, bleeding, lymphadenopathy
  5. Medication Reconciliation:

    • Complete medication list with doses and frequencies
    • Adherence assessment for each medication
    • Side effects or concerns
    • OTC medications, supplements, and herbals
    • Medications from other providers
    • Example: "Patient reports taking metformin 1000mg BID as prescribed. Occasionally misses evening dose. No GI side effects. Using ibuprofen 400mg PRN for knee pain 3-4x weekly."
  6. Health Maintenance History:

    • Cancer screenings: Colonoscopy, mammogram, Pap smear, lung CT, PSA
    • Immunizations: Flu, pneumonia, shingles, Tdap, COVID-19
    • Preventive labs: Lipid panel, HbA1c, metabolic panel
    • Lifestyle factors: Tobacco, alcohol, diet, exercise
    • Example: "Last colonoscopy 2020 (normal, repeat in 10 years). Received flu vaccine this season. Due for shingles vaccine. Walks 20 minutes daily."
  7. Social History:

    • Living situation and support system
    • Employment and occupational exposures
    • Tobacco: Pack-years, current status, cessation interest
    • Alcohol: Quantity, frequency, CAGE if indicated
    • Substance use: Illicit drugs, prescription misuse
    • Diet and exercise patterns
    • Sleep habits
  8. Family History:

    • First-degree relatives with major conditions
    • Age of onset for hereditary conditions
    • Causes of death in close relatives
    • Relevant for risk stratification (CAD, diabetes, cancer)

Example Subjective Section for Internal Medicine

Subjective (Internal Medicine)
 
 
CHIEF COMPLAINT: Annual wellness visit and chronic disease follow-up. Also reports increased thirst and urination x 3 weeks.
 
HISTORY OF PRESENT ILLNESS:
62-year-old male with type 2 diabetes, hypertension, hyperlipidemia, and obesity presenting for annual comprehensive visit. Reports new symptoms of polydipsia and polyuria over past 3 weeks. Drinking approximately 8-10 glasses of water daily (increased from baseline 4-5). Nocturia increased from 1x to 3-4x nightly. Denies dysuria, hematuria, or incontinence. Notes mild blurry vision intermittently. Reports fatigue and low energy. No recent illness, fever, or weight loss noted. Last A1c 3 months ago was 7.8%.
 
CHRONIC DISEASE REVIEW:
 
1. Type 2 Diabetes Mellitus (diagnosed 2015):
- Home glucose monitoring: Fasting 140-190 mg/dL (elevated from prior 120-150)
- Post-prandial readings: 180-240 mg/dL
- No hypoglycemic episodes
- Last A1c: 7.8% (3 months ago)
- Diabetic diet compliance: Fair, admits to increased carbohydrate intake recently
- No symptoms of neuropathy, reports annual eye exams up to date
- Last foot exam: 6 months ago - normal monofilament
 
2. Hypertension (diagnosed 2010):
- Home BP monitoring: 138-148/82-88 mmHg (above goal)
- Taking medications as prescribed
- Low sodium diet: Moderate compliance
- Denies headaches, vision changes, or chest pain
- No recent medication changes
 
3. Hyperlipidemia (diagnosed 2012):
- Last lipid panel (6 months ago): TC 198, LDL 112, HDL 42, TG 220
- Reports taking statin nightly
- No myalgias or muscle weakness
- Diet: Moderate fat intake
 
4. Obesity:
- Current weight 248 lbs, BMI 35.2
- Weight stable over past year
- Difficulty with exercise due to knee pain
- No structured weight loss program currently
 
REVIEW OF SYSTEMS:
- Constitutional: Fatigue x 3 weeks, no fever, no unintentional weight loss
- HEENT: Intermittent blurry vision (new), no hearing changes, wears reading glasses
- Cardiovascular: No chest pain, no palpitations, no lower extremity edema, no claudication
- Respiratory: Mild dyspnea on exertion (climbing 2 flights stairs), no cough, no wheezing
- GI: Good appetite, no nausea/vomiting, regular bowel movements, mild GERD controlled with omeprazole
- GU: Polydipsia and polyuria as above, nocturia 3-4x (increased), no dysuria, no hematuria, erectile dysfunction (unchanged)
- Musculoskeletal: Bilateral knee pain (osteoarthritis), worse with prolonged standing, using ibuprofen PRN
- Skin: No rashes, no new moles, no wounds
- Neurological: No headaches, no numbness/tingling in extremities, no weakness
- Psychiatric: Mood good, no depression, no anxiety, sleep disrupted by nocturia
- Endocrine: Symptoms as above consistent with possible hyperglycemia
- Hematologic: No easy bruising, no bleeding
 
CURRENT MEDICATIONS:
1. Metformin 1000mg BID - taking as prescribed, no GI issues
2. Glipizide 10mg BID - taking as prescribed
3. Lisinopril 20mg daily - taking as prescribed
4. Amlodipine 5mg daily - taking as prescribed
5. Atorvastatin 40mg at bedtime - taking as prescribed, no muscle pain
6. Omeprazole 20mg daily - taking for GERD
7. Aspirin 81mg daily - for cardiovascular prevention
8. Ibuprofen 400mg PRN - for knee pain, using 3-4x weekly
9. Vitamin D 2000 IU daily
10. Men's multivitamin daily
 
ALLERGIES: Penicillin (rash), Sulfa drugs (hives)
 
PAST MEDICAL HISTORY:
- Type 2 Diabetes Mellitus (2015)
- Hypertension (2010)
- Hyperlipidemia (2012)
- Obesity (BMI 35.2)
- Osteoarthritis bilateral knees
- GERD
- Erectile dysfunction
- Vitamin D deficiency
- Benign prostatic hyperplasia (mild)
- Appendectomy (1985)
 
SURGICAL HISTORY: Appendectomy (1985), Right knee arthroscopy (2018)
 
FAMILY HISTORY:
- Father: Type 2 diabetes, CAD, MI at age 68, died age 75
- Mother: Hypertension, stroke at age 72, alive age 84
- Brother: Type 2 diabetes, age 58
- Sister: Healthy, age 55
- No family history of cancer
 
SOCIAL HISTORY:
- Occupation: Accountant, sedentary work
- Living situation: Lives with wife, two adult children nearby
- Tobacco: Former smoker, quit 10 years ago, 20 pack-year history
- Alcohol: 1-2 beers on weekends, no binge drinking
- Recreational drugs: Denies
- Exercise: Walks 15-20 minutes daily when knee allows, no structured exercise program
- Diet: Follows 'general healthy diet,' admits to portion control issues and snacking
- Sleep: 6-7 hours, fragmented by nocturia
 
HEALTH MAINTENANCE STATUS:
- Colonoscopy: 2022, 2 adenomatous polyps removed, due 2025 (due now)
- Influenza vaccine: Received this season (October 2025)
- Pneumococcal vaccines: PCV20 received 2024
- Shingles vaccine: Not yet received (offered today)
- Tdap: Last 2020, due 2030
- COVID-19: Last booster 2024
- Diabetic eye exam: April 2025 - mild nonproliferative diabetic retinopathy
- Diabetic foot exam: June 2025 - normal monofilament, no ulcers
- AAA screening: Not done (indicated as former smoker age 65-75)
- Bone density: Not indicated at this time
 

Objective Section (O)

The Objective section in internal medicine requires a comprehensive physical examination with attention to findings relevant to chronic disease management, preventive care metrics, and acute concerns.

Objective Section (O) Components

  1. Vital Signs:

    • Blood pressure (may need orthostatic if indicated)
    • Heart rate and rhythm
    • Respiratory rate
    • Temperature
    • Weight with comparison to prior visits
    • Height (annually for seniors - height loss)
    • BMI calculation
    • Oxygen saturation if indicated
    • Example: "BP 146/88 mmHg, HR 78 regular, RR 14, Temp 98.4F, Weight 248 lbs (stable), Height 5'11", BMI 34.6"
  2. General Appearance:

    • Overall health status
    • Nutritional status
    • Apparent age vs. stated age
    • Level of distress
    • Affect and engagement
  3. Complete Physical Examination:

    • HEENT: Eyes (fundoscopic for diabetics), ears, oropharynx
    • Neck: Thyroid, lymph nodes, carotid bruits
    • Cardiovascular: Heart sounds, murmurs, peripheral pulses, edema
    • Respiratory: Breath sounds, effort
    • Abdomen: Organomegaly, masses, tenderness, AAA (if indicated)
    • Extremities: Pulses, edema, skin changes, diabetic foot exam
    • Skin: Lesions, concerning moles, acanthosis nigricans
    • Neurological: Sensation (monofilament for diabetics), reflexes
    • Psychiatric: Mood, affect, cognition if indicated
  4. Preventive Screening Results:

    • Recent cancer screening results
    • Immunization status
    • Risk assessment scores (ASCVD, Framingham)
  5. Chronic Disease Metrics:

    • Blood pressure tracking
    • Weight trend
    • Diabetic foot exam findings
    • Point-of-care glucose if available
  6. Laboratory Results:

    • Recent labs with dates and values
    • Trending of key values (A1c, lipids, renal function)
    • Abnormal values highlighted
    • Comparison to prior results

Example Objective Section for Internal Medicine

Objective (Internal Medicine)
 
 
VITAL SIGNS:
- Blood Pressure: 146/88 mmHg (right arm, sitting)
- Repeat BP: 142/86 mmHg (left arm, sitting)
- Heart Rate: 78 bpm, regular
- Respiratory Rate: 14 breaths/min
- Temperature: 98.4°F (oral)
- SpO2: 97% on room air
- Weight: 248 lbs (112.5 kg) - stable from 246 lbs 6 months ago
- Height: 5'11' (180 cm)
- BMI: 34.6 kg/m² (Class I Obesity)
 
GENERAL APPEARANCE:
Well-developed, obese male appearing stated age. In no acute distress. Alert and oriented, pleasant and cooperative. Appropriate affect.
 
HEENT:
- Head: Normocephalic, atraumatic
- Eyes: PERRL, EOMI. Fundoscopic exam: Microaneurysms noted bilaterally (consistent with known mild NPDR). No hemorrhages or exudates visualized. Unable to fully visualize periphery - recommend dilated exam by ophthalmology.
- Ears: TMs clear bilaterally, hearing grossly intact
- Nose: Patent, no discharge
- Throat: Oropharynx clear, moist mucous membranes, no lesions, dentition fair with some dental decay noted
- Neck: Supple, no lymphadenopathy, thyroid normal size without nodules, no carotid bruits
 
CARDIOVASCULAR:
- Regular rate and rhythm
- S1, S2 normal, no S3 or S4
- No murmurs, rubs, or gallops
- PMI non-displaced
- Peripheral pulses: Radial 2+ bilaterally, Dorsalis pedis 2+ bilaterally, Posterior tibial 2+ bilaterally
- No lower extremity edema
- No carotid bruits
- Capillary refill <2 seconds
 
RESPIRATORY:
- Clear to auscultation bilaterally
- No wheezes, rhonchi, or crackles
- Normal respiratory effort
- No use of accessory muscles
 
ABDOMEN:
- Obese, soft, non-tender, non-distended
- No organomegaly appreciated (limited by body habitus)
- No masses palpated
- No abdominal aortic bruit
- AAA palpation: Unable to reliably assess due to obesity - ultrasound indicated
- Normal bowel sounds in all quadrants
 
EXTREMITIES:
- No cyanosis, clubbing, or edema
- Bilateral knee crepitus with flexion, no effusion
- Range of motion limited by pain bilaterally
- Warm and well-perfused
 
SKIN:
- Acanthosis nigricans noted at posterior neck and axillae (insulin resistance marker)
- No suspicious lesions or moles
- Skin tags present at neck and axillae
- No ulcerations or wounds
- No evidence of fungal infections on feet
 
DIABETIC FOOT EXAMINATION:
- Inspection: No ulcers, calluses, or deformities. Toenails mildly thickened but no ingrown nails. No tinea pedis.
- Monofilament testing (10g): Intact sensation at all 10 sites bilaterally
- Vibration sense: Intact at great toes bilaterally
- Ankle reflexes: 1+ bilaterally (symmetric)
- Dorsalis pedis pulses: 2+ bilaterally
- Posterior tibial pulses: 2+ bilaterally
- Foot Risk Category: Low risk (no peripheral neuropathy, no deformity, no PAD)
 
NEUROLOGICAL:
- Alert and oriented x 4
- Cranial nerves II-XII intact
- Motor: 5/5 strength in all extremities
- Sensory: Intact to light touch, monofilament as above
- Reflexes: 2+ and symmetric upper extremities, 1+ bilateral ankles
- Gait: Antalgic gait favoring bilateral knees, otherwise steady
 
PSYCHIATRIC:
- Mood: 'Good'
- Affect: Appropriate, full range
- PHQ-2: 0/6 (negative screen)
- No psychomotor agitation or retardation
 
LABORATORY RESULTS (obtained today and recent):
 
Today's Point-of-Care Testing:
- Fingerstick glucose: 218 mg/dL (non-fasting, 2 hours post-breakfast)
 
Labs from Today (fasting):
- HbA1c: 8.9% (UP from 7.8% 3 months ago) - ABOVE GOAL
- Fasting glucose: 186 mg/dL (H)
- BMP:
- Sodium: 138 mEq/L
- Potassium: 4.2 mEq/L
- Chloride: 102 mEq/L
- CO2: 24 mEq/L
- BUN: 22 mg/dL
- Creatinine: 1.1 mg/dL (stable)
- eGFR: 78 mL/min/1.73m² (CKD Stage 2 - stable)
- Glucose: 186 mg/dL (H)
- Lipid Panel (fasting):
- Total Cholesterol: 212 mg/dL (H)
- LDL: 118 mg/dL (H - above goal <70 for diabetic with ASCVD risk)
- HDL: 40 mg/dL (L)
- Triglycerides: 268 mg/dL (H)
- Non-HDL Cholesterol: 172 mg/dL (H)
- Hepatic Panel: AST 28, ALT 42 (mildly elevated, stable), Alk Phos 78, Total Bili 0.8
- CBC: WBC 7.2, Hgb 14.8, Hct 44.2, Plt 234 - all within normal limits
- TSH: 2.4 mIU/L (normal)
- Vitamin D, 25-OH: 32 ng/mL (normal, on supplementation)
- Urine Albumin/Creatinine Ratio: 45 mg/g (MODERATELY INCREASED - A2 category)
 
Prior Labs for Comparison:
- HbA1c trend: 7.2% (12 mo ago) → 7.5% (9 mo ago) → 7.8% (3 mo ago) → 8.9% (today)
- Creatinine trend: 1.0 → 1.1 → 1.1 → 1.1 (stable)
- UACR trend: 25 → 32 → 45 mg/g (increasing - microalbuminuria progressing)
 
PREVENTIVE CARE STATUS:
- ASCVD 10-Year Risk Score: 18.2% (HIGH risk)
- Colonoscopy: Due now (last 2022 with polyps, 3-year interval recommended)
- AAA Ultrasound: Due (male, age 62, former smoker)
- Hepatitis C: Screened 2023 (negative)
- HIV: Screened 2023 (negative)
- Depression screening (PHQ-2): Negative today
- Alcohol screening (AUDIT-C): Score 3 (low risk)
- Fall risk: Not assessed (not indicated at age 62)
 
IMMUNIZATION STATUS:
- Influenza: Current (October 2025)
- Pneumococcal (PCV20): Complete (2024)
- Tdap: Current through 2030
- Zoster (Shingrix): Not received - OFFERED TODAY
- COVID-19: Booster 2024
- Hepatitis B: Series complete
 

Assessment Section (A)

The Assessment section synthesizes clinical findings with attention to problem list management, disease severity, quality measure compliance, and risk stratification.

Assessment Section (A) Components

  1. Problem List with ICD-10 Codes:

    • Active problems being addressed today
    • Chronic conditions requiring ongoing management
    • New diagnoses established
  2. Disease Control Assessment:

    • At goal vs. not at goal for each chronic condition
    • Improvement, stable, or worsening status
    • Barriers to control identified
  3. Risk Stratification:

    • ASCVD risk calculation
    • Diabetes complication risk
    • Cancer risk based on history
    • Falls risk if applicable
  4. Quality Measures Assessment:

    • MIPS/MACRA relevant measures
    • Preventive care gaps
    • Chronic disease quality metrics (A1c, BP, LDL)
  5. Clinical Reasoning:

    • Connection between symptoms and diagnoses
    • Differential diagnosis when indicated
    • Prognosis considerations

Example Assessment Section for Internal Medicine

Assessment (Internal Medicine)
 
 
ASSESSMENT:
 
PROBLEM LIST - ACTIVE:
 
1. TYPE 2 DIABETES MELLITUS, UNCONTROLLED (E11.65)
With chronic kidney disease stage 2 and mild nonproliferative diabetic retinopathy
 
- Current status: POORLY CONTROLLED - A1c 8.9% (goal <7.0% per ADA guidelines)
- Trend: Worsening (A1c increased from 7.8% to 8.9% over 3 months)
- New symptoms: Polydipsia, polyuria, nocturia, blurry vision - consistent with hyperglycemia
- Contributing factors identified:
* Dietary non-compliance (patient admits increased carbohydrate intake)
* Possible medication adherence issues (missed evening doses)
* No recent medication intensification despite prior A1c 7.8%
* Progressive beta-cell failure may be contributing
 
- Complications assessment:
* Retinopathy: Mild NPDR (stable per ophthalmology April 2025)
* Nephropathy: UACR 45 mg/g (increased from 25, now A2 category - microalbuminuria)
* Neuropathy: No clinical evidence (monofilament intact)
* Cardiovascular: High ASCVD risk (18.2%)
 
- Quality measure status: NOT AT GOAL
* A1c goal <7%: NOT MET (8.9%)
* Annual eye exam: MET (April 2025)
* Annual foot exam: MET (today)
* Nephropathy screening: MET (UACR done today)
* On statin: MET
* On ACE-I/ARB: MET
 
2. ESSENTIAL HYPERTENSION, NOT AT GOAL (I10)
 
- Current status: NOT CONTROLLED - BP 146/88 and 142/86 mmHg
- Goal: <130/80 mmHg per AHA/ACC guidelines for patient with diabetes and CKD
- Trend: Similar to prior visits, consistently above goal
- Currently on 2 antihypertensive agents (lisinopril 20mg, amlodipine 5mg)
- Adherence: Reports good compliance
- Lifestyle: Moderate sodium restriction
 
- Quality measure status: NOT AT GOAL (BP >130/80)
 
3. MIXED HYPERLIPIDEMIA, NOT AT GOAL (E78.2)
 
- Current status: NOT AT GOAL - LDL 118 mg/dL
- Goal: LDL <70 mg/dL for very high-risk patient (DM + ASCVD risk >20% or DM + CKD)
- Risk category: Very high risk (diabetes with microalbuminuria)
- Currently on moderate-intensity statin (atorvastatin 40mg)
- Triglycerides elevated at 268 mg/dL (contributing to residual risk)
- HDL low at 40 mg/dL
 
- Consider high-intensity statin + ezetimibe for LDL goal achievement
- ASCVD 10-year risk: 18.2% (high)
 
- Quality measure status: NOT AT GOAL (LDL >70 for very high risk)
 
4. OBESITY, CLASS I (E66.01)
BMI 34.6 kg/m²
 
- Weight stable at 248 lbs
- Contributing to insulin resistance, hypertension, and dyslipidemia
- Limited exercise due to knee pain
- Dietary challenges acknowledged by patient
- Consider GLP-1 RA for weight loss benefit in addition to glycemic control
 
5. CHRONIC KIDNEY DISEASE, STAGE 2 (N18.2)
eGFR 78 mL/min/1.73m², UACR 45 mg/g (A2)
 
- Etiology: Diabetic nephropathy (presumed)
- Trend: eGFR stable, but albuminuria increasing (25 → 45 mg/g over 18 months)
- Already on ACE-I (renoprotective)
- Consider SGLT2 inhibitor for additional renal protection
- Avoid nephrotoxins, dose-adjust medications as needed
 
6. OSTEOARTHRITIS, BILATERAL KNEES (M17.0)
 
- Limiting exercise capacity
- Using ibuprofen PRN (3-4x weekly) - CONCERN given CKD
- Recommend avoiding NSAIDs and switching to acetaminophen
- Physical therapy may help
- If severe, consider orthopedic referral
 
7. GERD, CONTROLLED (K21.0)
 
- On omeprazole 20mg daily, symptoms controlled
- Counsel on long-term PPI risks (consider step-down trial)
 
8. BENIGN PROSTATIC HYPERPLASIA (N40.0)
 
- Mild symptoms, nocturia currently attributed to hyperglycemia
- Reassess after glucose control improves
 
9. ERECTILE DYSFUNCTION (N52.9)
 
- Multifactorial: diabetes, vascular, possible medication-related
- Currently untreated - discuss options if patient interested
 
10. HEALTH MAINTENANCE GAPS IDENTIFIED:
 
- Colonoscopy: OVERDUE (last 2022 with adenomatous polyps, due 2025)
- AAA ultrasound: DUE (former smoker, male age 62)
- Shingrix vaccine: DUE (offered today)
- Pneumonia vaccine: COMPLETE
- Influenza: COMPLETE
 
CARDIOVASCULAR RISK ASSESSMENT:
- ASCVD 10-Year Risk Score: 18.2%
- Risk category: HIGH RISK
- Risk factors: Age 62, male, diabetes, hypertension, elevated LDL, low HDL, former smoker, family history
- Currently on aspirin, statin, ACE-I
 
QUALITY MEASURES SUMMARY (MIPS/Merit-Based Incentive Payment System):
| Measure | Goal | Current Status | Met? |
|---------|------|----------------|------|
| Diabetes: A1c <9% | <9% | 8.9% | YES |
| Diabetes: A1c <7% (ideal) | <7% | 8.9% | NO |
| Diabetes: Eye exam | Annual | April 2025 | YES |
| Diabetes: Foot exam | Annual | Today | YES |
| Diabetes: Nephropathy screening | Annual | Today (UACR) | YES |
| BP Control | <140/90 | 146/88 | NO |
| BP Control (DM) | <130/80 | 146/88 | NO |
| Statin for ASCVD/DM | On statin | Atorvastatin 40mg | YES |
| Tobacco cessation | Not using | Former smoker, quit | YES |
| Colorectal cancer screening | Current | Due for colonoscopy | NO |
| Influenza vaccine | Annual | Current | YES |
| Depression screening | Annual | PHQ-2 today | YES |
 

Plan Section (P)

The Plan section must address each active problem with specific interventions, following evidence-based protocols for chronic disease management and preventive care.

Plan Section (P) Components

  1. Chronic Disease Management Protocols:

    • Diabetes management (ADA guidelines)
    • Hypertension management (AHA/ACC guidelines)
    • Hyperlipidemia management (ACC/AHA cholesterol guidelines)
    • Specific medication adjustments with rationale
  2. Medication Changes:

    • New medications with indication, dose, and instructions
    • Dose adjustments with rationale
    • Medications discontinued with reason
    • Drug interaction considerations
  3. Preventive Care Orders:

    • Cancer screenings ordered (colonoscopy, mammogram, etc.)
    • Immunizations administered or ordered
    • Risk-based screenings (AAA ultrasound, lung CT)
  4. Lifestyle Counseling:

    • Diet recommendations
    • Exercise prescription
    • Weight management plan
    • Tobacco/alcohol counseling
  5. Care Coordination:

    • Specialist referrals with reason
    • Communication with other providers
    • Care team involvement
  6. Laboratory and Diagnostic Orders:

    • Follow-up labs with timing
    • Imaging studies
    • Other tests indicated
  7. Patient Education:

    • Topics discussed
    • Written materials provided
    • Teach-back confirmation
  8. Follow-up Plan:

    • Return visit timing and purpose
    • Interim phone/portal check-ins
    • When to seek urgent care

Example Plan Section for Internal Medicine

Plan (Internal Medicine)
 
 
PLAN:
 
1. TYPE 2 DIABETES MELLITUS - UNCONTROLLED:
 
Treatment Intensification per ADA Standards of Care 2025:
 
Current regimen failing (A1c 8.9% on metformin + sulfonylurea)
 
Medication Changes:
- CONTINUE metformin 1000mg BID (foundational therapy, renal function adequate)
- DISCONTINUE glipizide 10mg BID (switching to GLP-1 RA for better efficacy and weight benefit)
- START semaglutide (Ozempic):
* Week 1-4: 0.25mg subcutaneous weekly (titration dose)
* Week 5-8: 0.5mg subcutaneous weekly
* Week 9+: 1mg subcutaneous weekly (maintenance dose)
* Benefits: A1c reduction 1.5-2%, weight loss 5-10%, cardiovascular benefit
* Counseling: GI side effects (nausea, vomiting), inject same day each week, refrigerate pen
- START empagliflozin (Jardiance) 10mg daily:
* Benefits: A1c reduction 0.5-0.7%, renal protection (especially with albuminuria), cardiovascular benefit
* Counseling: Genital yeast infection risk, volume depletion, check renal function in 1 month
* Rationale: Patient has CKD stage 2 with microalbuminuria - SGLT2i indicated for renal protection per KDIGO guidelines
 
Monitoring:
- Continue home glucose monitoring: Fasting and one post-meal daily
- Recheck A1c in 3 months
- Recheck BMP and UACR in 1 month (after starting empagliflozin)
- Weight at each visit
 
Diabetes Education:
- Reviewed carbohydrate counting and portion control
- Discussed impact of dietary changes on glucose
- Provided written diet guidelines
- Semaglutide injection technique demonstrated; patient return-demonstrated successfully
 
2. HYPERTENSION - NOT AT GOAL:
 
Treatment Intensification per AHA/ACC Guidelines:
 
Goal: <130/80 mmHg for patient with diabetes and CKD
Current: 146/88 mmHg on lisinopril 20mg + amlodipine 5mg
 
Medication Changes:
- INCREASE lisinopril from 20mg to 40mg daily (maximize ACE-I for BP and renal protection)
- CONTINUE amlodipine 5mg daily
- Monitor for hyperkalemia with increased lisinopril dose
- If BP remains uncontrolled, add chlorthalidone 12.5mg at next visit
 
Lifestyle Reinforcement:
- Sodium restriction: <2,300 mg daily (ideally <1,500 mg for better BP control)
- DASH diet education provided
- Weight loss goal: 5-10% for BP benefit
- Physical activity as tolerated
 
Monitoring:
- Home BP monitoring: Check morning and evening, log values
- Recheck BP at 4-week follow-up
- Recheck BMP in 2 weeks (monitor potassium and creatinine with ACE-I increase)
 
3. HYPERLIPIDEMIA - NOT AT GOAL:
 
Treatment Intensification per ACC/AHA Cholesterol Guidelines:
 
Patient is VERY HIGH RISK (diabetes + CKD with albuminuria)
Goal: LDL <70 mg/dL
Current: LDL 118 mg/dL on atorvastatin 40mg (moderate-intensity)
 
Medication Changes:
- INCREASE atorvastatin from 40mg to 80mg at bedtime (high-intensity statin)
- ADD ezetimibe 10mg daily (for additional 18-25% LDL reduction)
- If LDL remains >70 mg/dL on statin + ezetimibe, consider PCSK9 inhibitor
 
Expected LDL reduction: From 118 to approximately 55-65 mg/dL
 
Triglycerides:
- Currently 268 mg/dL - address with lifestyle, glycemic control
- GLP-1 RA (semaglutide) will help lower triglycerides
- Recheck lipids in 3 months; if TG >500, consider fibrate or icosapent ethyl
 
Monitoring:
- Lipid panel in 3 months
- Hepatic panel in 6-8 weeks (baseline ALT mildly elevated)
- Monitor for muscle symptoms (myalgias)
 
4. OBESITY:
 
Weight Management Plan:
- Current BMI: 34.6 kg/m²
- Weight loss goal: 5-10% (12-25 lbs) over 6-12 months
- Semaglutide will provide pharmacologic support for weight loss (expected 5-15% loss)
 
Lifestyle Modifications:
- Caloric deficit: Target 500-750 kcal/day reduction
- Dietary counseling: Mediterranean-style or low-carbohydrate diet
- Physical activity: Start with 150 minutes/week moderate activity as knee allows
 
Referrals:
- Consider registered dietitian referral for intensive behavioral therapy
- Discuss bariatric surgery evaluation if BMI remains >35 with comorbidities after lifestyle + medication
 
5. CHRONIC KIDNEY DISEASE STAGE 2 WITH MICROALBUMINURIA:
 
Nephroprotective Strategy:
- Already on ACE-I (lisinopril) - will maximize dose
- Starting SGLT2i (empagliflozin) - provides additional 30-40% reduction in albuminuria progression
- Avoid NSAIDs (see below)
 
Monitoring:
- BMP and UACR in 1 month (after empagliflozin initiation)
- Expect 10-20% rise in creatinine with SGLT2i (acceptable if <30% and stabilizes)
- Annual UACR and eGFR thereafter
 
6. OSTEOARTHRITIS - BILATERAL KNEES:
 
Medication Change:
- DISCONTINUE ibuprofen (NSAID contraindicated with CKD - nephrotoxic and worsens hypertension)
- START acetaminophen 650mg every 6 hours PRN (max 3,000 mg/day)
- Topical diclofenac gel to affected knees BID PRN (minimal systemic absorption)
 
Non-Pharmacologic:
- Physical therapy referral for knee strengthening and low-impact exercise program
- Weight loss will significantly reduce knee stress
- Consider glucosamine/chondroitin if patient interested (limited evidence but safe)
 
If Pain Persists:
- Consider orthopedic referral for evaluation
- Intra-articular injections may be option
 
7. GERD:
 
- Continue omeprazole 20mg daily for now
- Counsel on long-term PPI risks (B12 deficiency, fracture risk, C. diff)
- Plan to trial step-down (to H2 blocker or PRN) after 3-6 months if symptoms stable
- Labs: Check B12 and magnesium at next visit
 
8. PREVENTIVE CARE - HEALTH MAINTENANCE:
 
Cancer Screening:
- COLONOSCOPY: Order referral to gastroenterology (due now - last 2022 with adenomatous polyps)
* Patient counseled on importance; will schedule within 4 weeks
- Continue annual skin exam (self-exam, low risk)
 
Vascular Screening:
- AAA ULTRASOUND: Order (one-time screening for male age 65-75 who has ever smoked)
* Patient qualifies at age 62 as former 20 pack-year smoker; guidelines support earlier screening
 
Immunizations:
- ADMINISTERED TODAY: Shingrix dose #1 (recombinant zoster vaccine) - left deltoid
* Dose #2 due in 2-6 months
- Influenza: Current
- Pneumococcal: Complete (PCV20 in 2024)
- COVID-19: Booster 2024, will need annual update
 
9. ERECTILE DYSFUNCTION:
 
- Discussed briefly; patient interested in treatment
- Will address at follow-up visit after metabolic issues stabilized
- Improvement in glycemic control and weight may help
- Options: PDE5 inhibitor (after cardiovascular assessment confirms low risk)
 
10. LABORATORY ORDERS:
 
- 2 weeks: BMP (monitor potassium and creatinine with lisinopril increase)
- 1 month: BMP, UACR (after empagliflozin started)
- 3 months: HbA1c, lipid panel, hepatic panel
- Annual: CBC, TSH, vitamin D, B12
 
11. REFERRALS:
 
- Gastroenterology: Colonoscopy (surveillance, polyp history)
- Physical Therapy: Knee strengthening, low-impact exercise program
- Registered Dietitian: Medical nutrition therapy for diabetes and weight management (consider referral if no improvement in 3 months)
- Ophthalmology: Confirm annual dilated eye exam scheduled
 
12. PATIENT EDUCATION PROVIDED:
 
Topics Discussed:
- Diabetes progression and importance of glycemic control
- New medication instructions (semaglutide injection, empagliflozin)
- Diet and lifestyle modifications
- Importance of stopping ibuprofen (kidney protection)
- Home glucose and blood pressure monitoring
- Signs of hypoglycemia (unlikely but reviewed)
- Shingles vaccine benefits and side effects
- Colonoscopy importance
 
Written Materials Provided:
- Semaglutide patient information sheet
- SGLT2 inhibitor information
- Low-sodium DASH diet handout
- Diabetes meal planning guide
 
Understanding Confirmed: Patient verbalized understanding of medication changes and agreed to treatment plan.
 
13. FOLLOW-UP:
 
- Phone call: 1 week - Nurse to check on medication tolerability, side effects
- Office visit: 4 weeks - BP recheck, lab review, medication tolerability
- Office visit: 3 months - A1c and lipid recheck, weight, overall assessment
 
Contact clinic for:
- Persistent nausea/vomiting (semaglutide side effect)
- Signs of urinary tract infection or genital yeast infection
- Dizziness, lightheadedness, or near-syncope
- Blood glucose <70 mg/dL
- Any concerning symptoms
 
TIME SPENT: 45 minutes, >50% of which was spent in counseling and coordination of care.
MDM COMPLEXITY: High (multiple chronic conditions, prescription drug management, discussion of data and management with patient)
 

AI-Assisted Documentation for Internal Medicine

As of 2025, 66% of healthcare providers utilize AI tools in their practice. AI scribes and ambient clinical intelligence are particularly valuable for internal medicine, where comprehensive documentation of multiple chronic conditions and preventive care is required.

How AI Helps Internal Medicine Documentation

  • Comprehensive ROS capture: Accurately documents extensive review of systems discussions
  • Medication reconciliation: Captures detailed medication lists with doses and adherence
  • Chronic disease tracking: Documents status updates for multiple conditions
  • Preventive care discussions: Records health maintenance counseling and decisions
  • Care coordination notes: Captures referral discussions and care planning
  • Patient education documentation: Records topics discussed and patient understanding

Internal Medicine-Specific AI Considerations

What AI captures well:

  • Chief complaint and HPI narrative
  • Detailed medication lists and dosages
  • Review of systems responses
  • Lifestyle counseling discussions
  • Patient-reported symptoms and concerns
  • Follow-up instructions

What requires careful review:

  • Vital sign accuracy (especially BP readings)
  • Laboratory values and trends
  • Physical examination findings (ensure all systems documented)
  • Medication doses and changes
  • ICD-10 codes (verify specificity)
  • Quality measure documentation elements
  • Risk score calculations

Tips for Using AI with Internal Medicine Documentation

  1. State medications clearly: "Lisinopril twenty milligrams once daily" not "lisinopril"
  2. Verbalize lab values: "The A1c is eight point nine percent, up from seven point eight"
  3. Document exam findings systematically: Work through each body system audibly
  4. State assessment clearly: "The diabetes is uncontrolled with A1c above goal"
  5. Specify preventive care status: "Colonoscopy is due, last done in twenty twenty-two"
  6. Review quality measures: Verify that documentation supports measure compliance
AI-Assisted Internal Medicine Documentation Checklist
 
 
AI DOCUMENTATION REVIEW CHECKLIST - INTERNAL MEDICINE
 
Before signing AI-generated notes, verify:
 
SUBJECTIVE:
[ ] Chief complaint accurately captured
[ ] HPI details complete (OLDCARTS elements)
[ ] All chronic conditions reviewed
[ ] Medication list complete with doses
[ ] Adherence and side effects documented
[ ] Health maintenance history accurate
[ ] Social history (tobacco, alcohol) current
[ ] ROS comprehensive and accurate
 
OBJECTIVE:
[ ] Vital signs correct (BP, weight, BMI)
[ ] All examination systems documented
[ ] Diabetic foot exam elements (if applicable)
[ ] Lab values accurate with dates
[ ] Comparison to prior values noted
[ ] Preventive screening status accurate
 
ASSESSMENT:
[ ] All active problems listed with ICD-10
[ ] Disease control status documented (at goal vs. not)
[ ] Quality measures addressed
[ ] Risk stratification included (if applicable)
[ ] Clinical reasoning clear
 
PLAN:
[ ] Each problem addressed
[ ] Medication changes clear with doses
[ ] Rationale for changes documented
[ ] Preventive care orders placed
[ ] Follow-up timing specified
[ ] Patient education documented
[ ] When to seek care instructions included
 
BILLING COMPLIANCE:
[ ] Time documented (if applicable)
[ ] MDM complexity supported
[ ] E&M level appropriate for documentation
 

For more details, see our complete AI-Assisted Documentation Guide.

Telehealth Internal Medicine Documentation

Telehealth has become integral to internal medicine practice for chronic disease management, medication management, and follow-up care. Per CMS 2026 guidelines, specific documentation requirements apply.

Telehealth-Appropriate Internal Medicine Services

  1. Chronic Care Management (CCM):

    • Monthly check-ins for chronic disease patients
    • Medication management and adjustments
    • Care coordination activities
    • Requires 20+ minutes of clinical staff time per month
  2. Annual Wellness Visit (AWV):

    • Can be conducted via telehealth with modifications
    • Health risk assessment
    • Preventive care planning
    • Advanced care planning discussions
  3. Chronic Disease Follow-Up:

    • Diabetes follow-up with home glucose data review
    • Hypertension management with home BP monitoring
    • Medication adjustment visits
  4. Remote Patient Monitoring (RPM):

    • Blood glucose monitoring data
    • Blood pressure monitoring data
    • Weight monitoring for CHF patients

Telehealth Documentation Requirements

For virtual internal medicine visits, document:

  1. Visit logistics:

    • Platform used (HIPAA-compliant)
    • Patient and provider locations
    • Consent for telehealth services
    • Audio/video quality
  2. Modified examination:

    • What could be assessed virtually
    • Patient self-reported findings
    • Home device data (BP, glucose, weight)
    • Examination limitations
  3. Remote monitoring data integration:

    • Home glucose logs
    • Home BP readings
    • Weight trends

Example Telehealth Chronic Disease Follow-Up

Telehealth Chronic Disease Follow-Up (Internal Medicine)
 
 
TELEHEALTH VISIT - INTERNAL MEDICINE
 
SESSION DETAILS:
- Platform: Epic MyChart Video (HIPAA-compliant)
- Patient Location: Home in [State]
- Provider Location: Primary Care Clinic, [State]
- Consent: Patient verbally consented to telehealth visit
- Video/Audio Quality: Good, clear visualization of patient
- Visit Type: Chronic Disease Follow-Up (Diabetes, Hypertension)
 
REMOTE MONITORING DATA REVIEW:
 
Home Glucose Log (past 2 weeks):
- Fasting readings: Range 118-142 mg/dL (avg 128) - improved from prior 140-190
- Post-meal readings: Range 145-180 mg/dL (avg 162) - improved from prior 180-240
- No hypoglycemic episodes (<70 mg/dL)
- Patient checking consistently 2x daily
 
Home Blood Pressure Log (past 2 weeks):
- Morning readings: Range 128-138/78-84 mmHg
- Evening readings: Range 124-134/76-82 mmHg
- Average: 132/80 mmHg - IMPROVED from prior 146/88 mmHg
- Device: Omron home monitor (validated)
 
Weight: 244 lbs (per home scale today) - DOWN 4 lbs from 248 lbs 4 weeks ago
 
SUBJECTIVE:
Patient presents for 4-week follow-up after medication adjustments.
 
Current Symptoms:
- Polydipsia and polyuria: Resolved - back to baseline
- Nocturia: Reduced from 3-4x to 1-2x nightly
- Vision: Blurriness resolved
- Energy: Improved
- No hypoglycemic symptoms
- Tolerating semaglutide well - mild nausea first week, now resolved
- Tolerating empagliflozin well - no yeast infections or UTI symptoms
- Denies dizziness or lightheadedness (no orthostatic symptoms)
 
Medication Adherence:
- Metformin: Taking as prescribed
- Semaglutide: Completed first 4 weeks at 0.25mg, ready to increase
- Empagliflozin: Taking daily, no issues
- Lisinopril 40mg: Taking as prescribed
- Amlodipine: Taking as prescribed
- Atorvastatin 80mg: No muscle aches
- Ezetimibe: Taking daily
 
Diet: Reports improved compliance with dietary recommendations. Reduced portion sizes, limiting carbohydrates, sodium restriction.
 
OBJECTIVE (Modified for Telehealth):
 
General: Patient appears well, alert, comfortable, in no distress via video.
 
Self-Reported/Patient-Measured:
- Blood Pressure: 130/78 mmHg (checked at start of visit with home device)
- Pulse: 74 bpm (per home device)
- Weight: 244 lbs (home scale)
- Temperature: 'Feels normal' - not measured
 
Visual Assessment:
- No visible distress
- No facial swelling or edema visible
- Appears well-nourished
- Good skin color
 
Patient Self-Exam (guided):
- Ankles: Patient reports and shows no visible swelling
- Feet: Patient inspected feet - reports no wounds, sores, or color changes visible
 
TELEHEALTH LIMITATIONS:
Unable to perform via telehealth: Blood pressure confirmation, comprehensive physical examination, diabetic foot monofilament testing, fundoscopic examination. In-person visit recommended within 3 months for complete examination.
 
LABORATORY RESULTS (obtained 1 week ago):
- BMP: Na 139, K 4.6, Cr 1.2 (slight increase from 1.1, acceptable), eGFR 72
- UACR: 38 mg/g (IMPROVED from 45 mg/g) - empagliflozin effect
 
ASSESSMENT:
 
1. Type 2 Diabetes Mellitus - IMPROVED
- Symptoms of hyperglycemia resolved
- Home glucose readings improved (fasting avg 128, post-meal avg 162)
- Awaiting A1c recheck at 3-month mark
- Tolerating semaglutide and empagliflozin
- Continue current regimen, advance semaglutide as planned
 
2. Hypertension - IMPROVED, APPROACHING GOAL
- Home BP average 132/80 mmHg (prior 146/88)
- Goal <130/80 mmHg - nearly at goal
- Lisinopril increased to 40mg, no issues
- Continue current regimen; may achieve goal with continued lifestyle changes
 
3. CKD Stage 2 - STABLE
- Creatinine 1.2 (acceptable small rise with SGLT2i initiation)
- UACR improved 45 → 38 mg/g
- Renal protection strategy working
 
4. Obesity - IMPROVING
- Weight 244 lbs (down from 248 lbs) - 4 lb loss in 4 weeks
- Attributed to dietary changes and semaglutide effect
- Trajectory is positive
 
PLAN:
 
1. Diabetes:
- Increase semaglutide to 0.5mg weekly starting this week (week 5)
- Continue metformin 1000mg BID
- Continue empagliflozin 10mg daily
- Continue home glucose monitoring (fasting + 1 post-meal daily)
- Recheck A1c at 3-month visit
 
2. Hypertension:
- Continue current regimen (lisinopril 40mg, amlodipine 5mg)
- Continue home BP monitoring
- Reinforce sodium restriction
- If BP remains slightly above goal, may add low-dose diuretic at next visit
 
3. CKD:
- Continue current renoprotective regimen
- Recheck BMP in 2 months
- Annual UACR
 
4. Weight Management:
- Continue current dietary approach
- Increase activity as tolerated
- Will increase to semaglutide 1mg at 8-week mark if tolerating
 
5. Pending Items:
- Colonoscopy: Scheduled for [DATE] - confirmed
- AAA ultrasound: Completed - normal (no aneurysm)
- Shingrix #2: Due in 1 month
 
6. Follow-up:
- Telehealth visit: 4 weeks (semaglutide tolerance, BP check)
- In-person visit: 3 months (comprehensive exam, A1c, lipids)
- Call if: dizziness, severe GI symptoms, signs of infection, glucose <70
 
Patient verbalized understanding of plan. Questions answered.
 

Annual Wellness Visit (Telehealth Version)

Annual Wellness Visit - Telehealth Template
 
 
MEDICARE ANNUAL WELLNESS VISIT - TELEHEALTH
 
VISIT INFORMATION:
- Visit Type: Annual Wellness Visit (AWV) via Telehealth
- Platform: [HIPAA-compliant platform]
- Patient Location: [State]
- Provider Location: [State]
- Consent: Verbal consent for telehealth AWV obtained
 
HEALTH RISK ASSESSMENT (HRA):
(Completed via patient portal prior to visit)
 
Demographics: [age, sex, race/ethnicity]
Self-Assessment of Health: [ ] Excellent [ ] Very Good [ ] Good [ ] Fair [ ] Poor
BMI: ___ (self-reported height/weight)
Blood Pressure: ___ (home monitor or last office reading)
 
FUNCTIONAL STATUS:
ADLs: [ ] Independent [ ] Needs assistance with: _______________
IADLs: [ ] Independent [ ] Needs assistance with: _______________
Hearing: [ ] Normal [ ] Difficulty
Vision: [ ] Normal [ ] Difficulty (wears corrective lenses: Y/N)
Falls in past year: [ ] None [ ] 1 [ ] 2+ - Details: _______________
Fear of falling: [ ] No [ ] Yes
Home safety concerns: _______________
 
COGNITIVE SCREENING:
[ ] No concerns noted
[ ] Concerns identified: _______________
[ ] Formal screening performed: _______________ Score: ___
 
DEPRESSION SCREENING:
PHQ-2: ___/6
[ ] Negative (score <3)
[ ] Positive (score ≥3) - PHQ-9 administered: ___/27
 
BEHAVIORAL RISKS:
Tobacco: [ ] Never [ ] Former [ ] Current - pack-years: ___
Alcohol: [ ] None [ ] Occasional [ ] Daily - AUDIT-C score: ___
Physical Activity: ___ minutes/week
Diet: _______________
Seatbelt use: [ ] Always [ ] Sometimes [ ] Never
Home safety: _______________
 
CURRENT MEDICATIONS:
[Complete medication list reviewed via shared screen/patient report]
 
PREVENTIVE CARE STATUS:
 
Cancer Screenings:
| Screening | Last Done | Due | Action |
|-----------|-----------|-----|--------|
| Colonoscopy | | | |
| Mammogram | | | |
| Pap smear | | | |
| Lung CT (if indicated) | | | |
| PSA (if discussed) | | | |
 
Immunizations:
| Vaccine | Last Dose | Due | Action |
|---------|-----------|-----|--------|
| Influenza | | | |
| Pneumococcal (PCV20/PPSV23) | | | |
| Tdap/Td | | | |
| Shingrix | | | |
| COVID-19 | | | |
| Hepatitis B | | | |
 
Other Screenings:
- Bone density (if indicated): _______________
- AAA ultrasound (if indicated): _______________
- Hepatitis C (one-time): _______________
- HIV (one-time): _______________
- Diabetes screening: _______________
- Lipid panel: _______________
 
ADVANCE CARE PLANNING (if discussed):
- Healthcare proxy: [ ] Documented [ ] Not documented [ ] Discussed today
- Living will: [ ] Documented [ ] Not documented [ ] Discussed today
- POLST/MOLST: [ ] Completed [ ] Not applicable [ ] Discussed today
- Code status discussed: [ ] Yes [ ] No
- Time spent on ACP: ___ minutes
 
PERSONALIZED PREVENTION PLAN:
 
Goals for Coming Year:
1. _______________
2. _______________
3. _______________
 
Health Risks Identified:
1. _______________
2. _______________
3. _______________
 
Preventive Services Ordered/Recommended:
1. _______________
2. _______________
3. _______________
 
Referrals:
_______________
 
TELEHEALTH LIMITATIONS:
- Vital signs not measured (relied on home monitoring/self-report)
- Physical examination not performed
- In-person visit recommended for: _______________
 
FOLLOW-UP:
- Next AWV: 12 months
- Interim visits as needed for chronic disease management
 
Time spent on AWV: ___ minutes
If >30 minutes spent on ACP, bill separately: [ ] Yes [ ] No
 

For complete telehealth documentation guidance, see our Telehealth SOAP Notes Guide.

Free Internal Medicine SOAP Note Templates

Chronic Disease Follow-Up Template

CHRONIC DISEASE FOLLOW-UP - INTERNAL MEDICINE
 
PATIENT: _______________ DOB: ___________ DATE: ___________
VISIT TYPE: [ ] In-Person [ ] Telehealth
 
═══════════════════════════════════════
SUBJECTIVE
═══════════════════════════════════════
 
REASON FOR VISIT:
[ ] Routine chronic disease follow-up
[ ] Medication refill
[ ] Symptom evaluation: _______________
 
CHRONIC CONDITIONS REVIEWED:
 
1. DIABETES (if applicable):
- Home glucose log reviewed: [ ] Yes [ ] No
- Fasting range: ___-___ mg/dL
- Post-meal range: ___-___ mg/dL
- Hypoglycemic episodes: [ ] None [ ] Yes: _______________
- Symptoms: [ ] Polyuria [ ] Polydipsia [ ] Neuropathy sx [ ] None
- Self-management: [ ] Diet adherent [ ] Checking glucose [ ] Foot care
 
2. HYPERTENSION (if applicable):
- Home BP log reviewed: [ ] Yes [ ] No
- BP range: ___/___ to ___/___ mmHg
- Symptoms: [ ] Headaches [ ] Dizziness [ ] None
- Medication adherence: [ ] Good [ ] Missed doses: ___
 
3. HYPERLIPIDEMIA (if applicable):
- Statin tolerability: [ ] Good [ ] Myalgias [ ] Other: ___
- Diet compliance: [ ] Good [ ] Fair [ ] Poor
 
4. OTHER CHRONIC CONDITIONS:
_____________________________________________
 
MEDICATION RECONCILIATION:
| Medication | Dose | Frequency | Adherence | Issues |
|------------|------|-----------|-----------|--------|
| | | | | |
| | | | | |
| | | | | |
 
REVIEW OF SYSTEMS:
- Constitutional: _______________
- Cardiovascular: _______________
- Respiratory: _______________
- GI: _______________
- GU: _______________
- Neurological: _______________
- Psychiatric: _______________
 
═══════════════════════════════════════
OBJECTIVE
═══════════════════════════════════════
 
VITAL SIGNS:
- BP: ___/___ mmHg Repeat if elevated: ___/___ mmHg
- HR: ___ bpm RR: ___ Temp: ___
- Weight: ___ lbs (___ kg) Previous: ___ Change: ___
- BMI: ___ SpO2: ___%
 
GENERAL: _______________
 
PHYSICAL EXAMINATION:
- HEENT: _______________
- Neck: _______________
- Cardiovascular: _______________
- Respiratory: _______________
- Abdomen: _______________
- Extremities: _______________
- Neurological: _______________
 
DIABETIC FOOT EXAM (if applicable):
- Inspection: [ ] Normal [ ] Abnormal: _______________
- Monofilament: [ ] Intact [ ] Diminished: _______________
- Pulses: DP ___ PT ___
- Foot risk category: [ ] Low [ ] Moderate [ ] High
 
LABORATORY RESULTS:
- HbA1c: ___% (date: ___) Goal: <___% Status: [ ] At goal [ ] Above goal
- Fasting glucose: ___ mg/dL
- Lipid panel: TC ___ LDL ___ HDL ___ TG ___ (date: ___)
- BMP: Na ___ K ___ Cr ___ eGFR ___
- UACR: ___ mg/g (date: ___)
- Other: _______________
 
═══════════════════════════════════════
ASSESSMENT
═══════════════════════════════════════
 
PROBLEM LIST:
 
1. _________________ (ICD-10: _______)
Status: [ ] Controlled [ ] Not controlled [ ] Improved [ ] Worsened
At goal: [ ] Yes [ ] No Goal: _______________
 
2. _________________ (ICD-10: _______)
Status: [ ] Controlled [ ] Not controlled [ ] Improved [ ] Worsened
At goal: [ ] Yes [ ] No Goal: _______________
 
3. _________________ (ICD-10: _______)
Status: [ ] Controlled [ ] Not controlled [ ] Improved [ ] Worsened
At goal: [ ] Yes [ ] No Goal: _______________
 
CARDIOVASCULAR RISK:
- ASCVD 10-year risk: ___% (if calculated)
- Risk category: [ ] Low [ ] Moderate [ ] High [ ] Very high
 
QUALITY MEASURES:
| Measure | Goal | Status | Met? |
|---------|------|--------|------|
| A1c | <___% | | |
| BP | <___/___ | | |
| LDL | <___ | | |
 
═══════════════════════════════════════
PLAN
═══════════════════════════════════════
 
1. DIABETES:
[ ] Continue current regimen
[ ] Adjust medications: _______________
[ ] A1c recheck in ___ months
[ ] Referral to: [ ] Ophthalmology [ ] Podiatry [ ] Endocrinology
 
2. HYPERTENSION:
[ ] Continue current regimen
[ ] Adjust medications: _______________
[ ] Home BP monitoring: _______________
 
3. HYPERLIPIDEMIA:
[ ] Continue current regimen
[ ] Adjust medications: _______________
[ ] Lipid panel in ___ months
 
4. MEDICATION CHANGES:
- Start: _______________
- Stop: _______________
- Adjust: _______________
 
5. LIFESTYLE COUNSELING:
[ ] Diet [ ] Exercise [ ] Weight [ ] Tobacco [ ] Alcohol
 
6. PREVENTIVE CARE:
[ ] Immunizations: _______________
[ ] Screenings ordered: _______________
 
7. LABORATORY ORDERS:
_______________
 
8. REFERRALS:
_______________
 
9. FOLLOW-UP:
- Next visit: ___ weeks/months
- Reason: _______________
- Call if: _______________
 
PATIENT EDUCATION: _______________
Understanding confirmed: [ ] Yes [ ] No
 
Time: ___ minutes Complexity: [ ] Low [ ] Moderate [ ] High
 
Provider: _______________ Date: _______________
 

Annual Comprehensive Visit Template

ANNUAL COMPREHENSIVE VISIT - INTERNAL MEDICINE
 
PATIENT: _______________ DOB: ___________ DATE: ___________
 
═══════════════════════════════════════
SUBJECTIVE
═══════════════════════════════════════
 
REASON FOR VISIT: Annual comprehensive examination and preventive care
 
INTERVAL HISTORY:
- Hospitalizations since last visit: [ ] None [ ] Yes: _______________
- ER visits since last visit: [ ] None [ ] Yes: _______________
- Specialist visits: _______________
- New diagnoses: _______________
 
CHRONIC DISEASE REVIEW:
1. _______________: _______________
2. _______________: _______________
3. _______________: _______________
 
COMPLETE MEDICATION RECONCILIATION:
(List all medications including OTC, supplements, herbals)
| Medication | Dose | Frequency | Indication | Adherence |
|------------|------|-----------|------------|-----------|
| | | | | |
| | | | | |
 
ALLERGIES: _______________
 
COMPREHENSIVE REVIEW OF SYSTEMS:
- Constitutional: _______________
- HEENT: _______________
- Cardiovascular: _______________
- Respiratory: _______________
- GI: _______________
- GU: _______________
- Musculoskeletal: _______________
- Skin: _______________
- Neurological: _______________
- Psychiatric: _______________
- Endocrine: _______________
- Hematologic/Lymphatic: _______________
 
SOCIAL HISTORY:
- Living situation: _______________
- Occupation: _______________
- Tobacco: [ ] Never [ ] Former (quit: ___, pack-years: ___) [ ] Current (___/day)
- Alcohol: [ ] None [ ] Occasional [ ] Daily (amount: ___)
- Recreational drugs: [ ] None [ ] Yes: _______________
- Exercise: ___ minutes/week, type: _______________
- Diet: _______________
- Sleep: ___ hours/night, quality: _______________
- Stress level: _______________
- Safety: Seatbelts [ ] Y [ ] N, Firearms [ ] Y [ ] N, DV screen [ ] Neg [ ] Pos
 
FAMILY HISTORY:
- CAD: _______________
- Diabetes: _______________
- Cancer: _______________
- Stroke: _______________
- Other: _______________
 
HEALTH MAINTENANCE STATUS:
Screenings:
- Colonoscopy: Last ___, Next due ___
- Mammogram: Last ___, Next due ___
- Pap smear: Last ___, Next due ___
- Lung CT: [ ] Not indicated [ ] Due [ ] Done ___
- PSA: [ ] Not discussed [ ] Declined [ ] Done ___
- AAA ultrasound: [ ] Not indicated [ ] Due [ ] Done ___
- Bone density: [ ] Not indicated [ ] Due [ ] Done ___
- Hepatitis C: [ ] Screened [ ] Not screened
- HIV: [ ] Screened [ ] Not screened
 
Immunizations:
- Influenza: [ ] Current [ ] Due
- Pneumococcal: [ ] Complete [ ] Due [ ] N/A
- Tdap/Td: Last ___, Next due ___
- Zoster: [ ] Complete [ ] Due [ ] N/A
- COVID-19: [ ] Current [ ] Due
- Hepatitis B: [ ] Complete [ ] Due [ ] N/A
 
═══════════════════════════════════════
OBJECTIVE
═══════════════════════════════════════
 
VITAL SIGNS:
- BP: ___/___ mmHg
- HR: ___ bpm
- RR: ___
- Temp: ___
- Weight: ___ lbs (___ kg) Height: ___ BMI: ___
- SpO2: ___%
 
GENERAL APPEARANCE: _______________
 
COMPREHENSIVE PHYSICAL EXAMINATION:
 
HEENT:
- Head: _______________
- Eyes: _______________
- Ears: _______________
- Nose: _______________
- Throat/Oral: _______________
 
NECK: _______________
 
LYMPHATIC: _______________
 
CARDIOVASCULAR: _______________
 
RESPIRATORY: _______________
 
BREAST (if applicable): _______________
 
ABDOMEN: _______________
 
GENITOURINARY (if applicable): _______________
 
RECTAL/PROSTATE (if applicable): _______________
 
EXTREMITIES: _______________
 
SKIN: _______________
 
NEUROLOGICAL: _______________
 
PSYCHIATRIC: _______________
 
MUSCULOSKELETAL: _______________
 
SCREENING ASSESSMENTS:
- PHQ-2/PHQ-9: ___/___
- AUDIT-C: ___
- Fall risk: _______________
- Cognitive screen (if indicated): _______________
 
LABORATORY RESULTS:
- CBC: WBC ___ Hgb ___ Plt ___
- CMP: Na ___ K ___ Cr ___ eGFR ___ Glucose ___
- Lipid panel: TC ___ LDL ___ HDL ___ TG ___
- HbA1c: ___% (if applicable)
- TSH: ___
- Vitamin D: ___
- Urinalysis: _______________
- Other: _______________
 
═══════════════════════════════════════
ASSESSMENT
═══════════════════════════════════════
 
ACTIVE PROBLEM LIST:
1. _______________ (ICD-10: ___) - _______________
2. _______________ (ICD-10: ___) - _______________
3. _______________ (ICD-10: ___) - _______________
 
HEALTH MAINTENANCE SUMMARY:
| Item | Status | Action Needed |
|------|--------|---------------|
| | | |
 
RISK ASSESSMENT:
- Cardiovascular risk (ASCVD): ___%
- Diabetes risk: _______________
- Cancer risk factors: _______________
- Falls risk: _______________
 
═══════════════════════════════════════
PLAN
═══════════════════════════════════════
 
CHRONIC DISEASE MANAGEMENT:
1. _______________
2. _______________
3. _______________
 
PREVENTIVE CARE ORDERS:
Screenings:
[ ] Colonoscopy referral
[ ] Mammogram order
[ ] Pap smear order
[ ] Lung CT order
[ ] AAA ultrasound order
[ ] Bone density order
[ ] Other: _______________
 
Immunizations Administered:
[ ] Influenza (lot: ___, site: ___)
[ ] Pneumococcal (lot: ___, site: ___)
[ ] Tdap/Td (lot: ___, site: ___)
[ ] Zoster (lot: ___, site: ___)
[ ] COVID-19 (lot: ___, site: ___)
[ ] Other: _______________
 
LIFESTYLE COUNSELING:
[ ] Diet counseling: _______________
[ ] Exercise prescription: _______________
[ ] Weight management: _______________
[ ] Tobacco cessation: _______________
[ ] Alcohol reduction: _______________
[ ] Sleep hygiene: _______________
 
MEDICATION CHANGES:
- Continue: _______________
- Start: _______________
- Stop: _______________
- Adjust: _______________
 
LABORATORY ORDERS:
[ ] Recheck in ___ months: _______________
 
REFERRALS:
_______________
 
PATIENT EDUCATION:
Topics discussed: _______________
Materials provided: _______________
 
ADVANCE CARE PLANNING:
[ ] Discussed today
[ ] Healthcare proxy documented
[ ] Code status discussed
 
FOLLOW-UP:
- Annual visit: 12 months
- Chronic disease follow-up: ___ months
- Other: _______________
 
Time spent: ___ minutes
Complexity: [ ] Low [ ] Moderate [ ] High
 
Provider: _______________ Date: _______________
 

Frequently Asked Questions

For complex patients with multiple chronic conditions, document each condition separately in both the Assessment and Plan sections. For each condition, include: current control status (at goal vs. not at goal), relevant metrics (A1c for diabetes, BP for hypertension, LDL for hyperlipidemia), comparison to prior values showing trends, barriers to control identified, and the specific treatment plan addressing that condition. Use a problem-oriented approach with ICD-10 codes for each diagnosis. This structure supports appropriate billing complexity and demonstrates comprehensive care coordination.

MIPS quality measures for internal medicine require specific documentation elements: (1) Diabetes: A1c value with date, annual dilated eye exam, annual foot exam with monofilament testing, nephropathy screening (UACR), statin prescription status. (2) Hypertension: BP reading with goal comparison (<130/80 or <140/90 depending on risk). (3) Preventive care: Colonoscopy status, mammogram status, flu vaccine, pneumococcal vaccine, depression screening (PHQ-2/9), tobacco use and cessation counseling. Document these elements explicitly with dates and results to ensure quality measure credit.

Complete medication reconciliation should include: (1) Full list of all current medications with exact doses, frequencies, and routes. (2) Adherence assessment for each medication. (3) Side effects or tolerability issues. (4) Over-the-counter medications, supplements, and herbals. (5) Medications prescribed by other providers. (6) Allergies and adverse drug reactions with specific reactions noted. (7) Any discrepancies identified and resolved. Document who provided the information and any changes made. Example: 'Medication list reviewed with patient and updated. Patient taking metformin 1000mg BID (confirms adherence). Ibuprofen 400mg PRN discontinued due to CKD. Allergies confirmed: Penicillin (rash).'

AWV documentation requires: (1) Health Risk Assessment (HRA) completion - either via questionnaire or interview. (2) Medical and family history update. (3) Current medications and providers list. (4) Height, weight, BMI, and blood pressure. (5) Cognitive assessment (observation or formal screening). (6) Depression screening (PHQ-2). (7) Functional ability and safety assessment. (8) Review of preventive services with personalized prevention plan. (9) Advanced care planning discussion (optional but separately billable). (10) Risk factors and conditions identified. Document the time spent and ensure the visit focuses on prevention rather than acute complaints.

Document the ASCVD 10-year risk score calculation with the percentage result and risk category (low <5%, borderline 5-7.5%, intermediate 7.5-20%, high >20%). Include risk factors considered: age, sex, race, total cholesterol, HDL, systolic BP, BP treatment status, diabetes status, and smoking status. For statin decisions, document: current LDL level, goal LDL based on risk category, statin intensity appropriate for risk level (moderate vs. high-intensity), patient discussion of risks/benefits, and patient decision. If statin declined, document shared decision-making discussion.

Transitional care documentation should include: (1) Date and reason for hospitalization. (2) Discharge diagnoses and procedures performed. (3) Review of discharge summary and recommendations. (4) Medication changes made during hospitalization with reconciliation to current list. (5) Pending tests or follow-up appointments scheduled. (6) Assessment of patient understanding of discharge instructions. (7) New symptoms or concerns since discharge. (8) Physical exam focused on hospital-related issues. (9) Plan for addressing each hospital-related issue with follow-up timing. Document communication with specialists or hospital providers if applicable. This supports TCM billing codes.

Yes, SOAPNoteAI.com is an AI-powered documentation platform designed for healthcare providers across all specialties, including internal medicine. It is fully HIPAA-compliant with a signed Business Associate Agreement (BAA) to protect patient data. The platform works on iPhone, iPad, and web browsers, allowing you to dictate patient encounters and receive comprehensive SOAP notes with proper formatting for chronic disease management, preventive care, medication reconciliation, and quality measures. The AI understands internal medicine-specific documentation requirements including MIPS measures, helping ensure compliance while reducing documentation time by up to 50%.

Medical Disclaimer: This content is for educational purposes only and should not replace professional medical judgment. Always consult current clinical guidelines and your institution's policies.

Was this page helpful?